Gudrun Meinhardt
About
Gudrun Meinhardt is a scholar working on Molecular Biology, Obstetrics and Gynecology and Oncology.
According to data from OpenAlex, Gudrun Meinhardt has authored 63 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Molecular Biology, 19 papers in Obstetrics and Gynecology and 15 papers in Oncology. Recurrent topics in Gudrun Meinhardt's work include Pregnancy and preeclampsia studies (19 papers), Hepatocellular Carcinoma Treatment and Prognosis (13 papers) and Reproductive System and Pregnancy (11 papers). Gudrun Meinhardt is often cited by papers focused on Pregnancy and preeclampsia studies (19 papers), Hepatocellular Carcinoma Treatment and Prognosis (13 papers) and Reproductive System and Pregnancy (11 papers). Gudrun Meinhardt collaborates with scholars based in Austria, United States and Germany. Gudrun Meinhardt's co-authors include Martin Knöfler, Jürgen Pollheimer, Sandra Haider, Christian Fiala, Surender Kharbanda, Leila Saleh, May C. Robertson, Tariq Ghayur, Yoshinobu Manome and Robert Kamen and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and The EMBO Journal.
In The Last Decade
Gudrun Meinhardt
61 papers receiving 2.3k citations
Hit Papers
Peers
Gudrun Meinhardt
Yoshito Terai Japan
Clyde Riley Australia
Julian A. Gingold United States
Toshio Hirakawa Japan
Josette Badet France
Akira Hirasawa Japan
Adam J. Krieg United States
Laith Dabbagh Canada
Carmela Calés Spain
Ian Tomlinson United Kingdom
Citations per year, relative to Gudrun Meinhardt Gudrun Meinhardt (= 1×)
peers
Yoshito Terai
Countries citing papers authored by Gudrun Meinhardt
Since
Specialization
Citations
This map shows the geographic impact of Gudrun Meinhardt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gudrun Meinhardt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gudrun Meinhardt more than expected).
Fields of papers citing papers by Gudrun Meinhardt
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Gudrun Meinhardt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gudrun Meinhardt. The network helps show where Gudrun Meinhardt may publish in the future.
Co-authorship network of co-authors of Gudrun Meinhardt
This figure shows the co-authorship network connecting the top 25 collaborators of Gudrun Meinhardt. A scholar is included among the top collaborators of Gudrun Meinhardt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gudrun Meinhardt. Gudrun Meinhardt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Dietrich, Bianca, Victoria Kunihs, Gudrun Meinhardt, et al.. (2023). NOTCH3 signalling controls human trophoblast stem cell expansion and differentiation. Development. 150(22).
2.
Haider, Sandra, Bianca Dietrich, Victoria Kunihs, et al.. (2022). Transforming growth factor-β signaling governs the differentiation program of extravillous trophoblasts in the developing human placenta. Proceedings of the National Academy of Sciences. 119(28). e2120667119–e2120667119.
3.
Ray, Soma, Ram Kumar, Gudrun Meinhardt, et al.. (2022). Hippo signaling cofactor, WWTR1, at the crossroads of human trophoblast progenitor self-renewal and differentiation. Proceedings of the National Academy of Sciences. 119(36). e2204069119–e2204069119.
4.
Ku, Geoffrey Y., Maria Di Bartolomeo, Ian Chau, et al.. (2022). 1205MO Updated analysis of DESTINY-Gastric02: A phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable/metastatic gastric/gastroesophageal junction (GEJ) cancer who progressed on or after trastuzumab-containing regimen. Annals of Oncology. 33. S1100–S1100.
5.
Zhang, Elisa, Roberta L. Hannibal, Janet Song, et al.. (2021). PRG2 and AQPEP are misexpressed in fetal membranes in placenta previa and percreta †. Biology of Reproduction. 105(1). 244–257.
6.
Shitara, Kohei, Fábio Franke, Yoshiaki Kawaguchi, et al.. (2021). 1436TiP Trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-positive gastric cancer (GC) or gastroesophageal junction (GEJ) adenocarcinoma who have progressed on or after a trastuzumab-containing regimen (DESTINY-gastric04, DG-04): A randomized phase III study. Annals of Oncology. 32. S1073–S1073.
7.
Cutsem, Eric Van, Maria Di Bartolomeo, Ian Chau, et al.. (2021). LBA55 Primary analysis of a phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer who progressed on or after a trastuzumab-containing regimen. Annals of Oncology. 32. S1332–S1332.
8.
Smit, Egbert F., B.T. Li, Julien Mazières, et al.. (2021). 1361TiP Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC): A phase (ph) II study (DESTINY-Lung02). Annals of Oncology. 32. S1032–S1033.
9.
Szilágyi, András, Roberto Romero, Yi Xu, et al.. (2020). Placenta-Specific Genes, Their Regulation During Villous Trophoblast Differentiation and Dysregulation in Preterm Preeclampsia. International Journal of Molecular Sciences. 21(2). 628–628.
10.
Huang, Liping, Yoriko De Sanctis, Minghua Shan, et al.. (2017). Correlation between overall survival (OS) and time to progression (TTP) and between OS and response rate (RR) by RECIST in advanced hepatocellular carcinoma (HCC). Annals of Oncology. 28. v239–v239.
11.
Teufel, Michael, Karl Köchert, Gudrun Meinhardt, et al.. (2017). Protein biomarkers as predictors of outcome with regorafenib (REG) in patients (pts) with hepatocellular carcinoma (HCC) in the RESORCE trial. Annals of Oncology. 28. v213–v213.
12.
Teufel, Michael, Henrik Seidel, Karl Köchert, et al.. (2017). Circulating miRNA biomarkers predicting regorafenib (REG) clinical benefit in patients with hepatocellular carcinoma (HCC) in the RESORCE trial. Annals of Oncology. 28. v240–v240.
13.
Bruix, Jordi, Philippe Merle, Alessandro Granito, et al.. (2016). Efficacy, safety, and health-related quality of life (HRQoL) of regorafenib in patients with hepatocellular carcinoma (HCC) progressing on sorafenib: Results of the international, double-blind phase 3 RESORCE trial. Annals of Oncology. 27. vi564–vi564.
14.
Meinhardt, Gudrun, Jordi Bruix, Josep M. Llovet, Ann‐Lii Cheng, & Christian Kappeler. (2016). Analysis of tumor growth rate for advanced hepatocellular cancer patients receiving placebo or sorafenib in the phase 3 SHARP and Asia Pacific trials. Annals of Oncology. 27. vi237–vi237.
15.
Brose, Marcia S., Barbara Jarząb, Rossella Elisei, et al.. (2016). Final overall survival analysis of patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) treated with sorafenib in the phase 3 DECISION trial: An exploratory crossover adjustment analyses. Annals of Oncology. 27. vi329–vi329.
16.
Kappeler, Christian, Gudrun Meinhardt, Rossella Elisei, Marcia S. Brose, & Martin Schlumberger. (2016). Tumor growth rate analysis of progression-free survival (PFS) and overall survival (OS) for thyroid cancer patients receiving placebo or sorafenib in the phase 3 DECISION trial. Annals of Oncology. 27. vi331–vi331.
17.
Meinhardt, Gudrun, et al.. (2015). ERBB2 gene amplification increases during the transition of proximal EGFR+ to distal HLA-G+ first trimester cell column trophoblasts. Placenta. 36(8). 803–808.
18.
Wilson, P. M., Dongyun Yang, Mizutomo Azuma, et al.. (2012). Intratumoral expression profiling of genes involved in angiogenesis in colorectal cancer patients treated with chemotherapy plus the VEGFR inhibitor PTK787/ZK 222584 (vatalanib). The Pharmacogenomics Journal. 13(5). 410–416.
19.
Husslein, H, Sandra Haider, Gudrun Meinhardt, et al.. (2009). Expression, Regulation and Functional Characterization of Matrix Metalloproteinase-3 of Human Trophoblast. Placenta. 30(3). 284–291.
20.
Schmidmaier, Ralf, et al.. (2006). Vascular ectasia of the whole intestine as a cause of recurrent gastrointestinal bleeding after high-dose chemotherapy. Endoscopy. 38(9). 940–942.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Yoshito Terai Breakdown of academic impact, for papers by Clyde Riley Breakdown of academic impact, for papers by Julian A. Gingold Breakdown of academic impact, for papers by Toshio Hirakawa Breakdown of academic impact, for papers by Josette Badet Breakdown of academic impact, for papers by Akira Hirasawa Breakdown of academic impact, for papers by Adam J. Krieg Breakdown of academic impact, for papers by Laith Dabbagh Breakdown of academic impact, for papers by Carmela Calés Breakdown of academic impact, for papers by Ian Tomlinson